Dietary intervention rescues a bone porosity phenotype in a murine model of Neurofibromatosis Type 1 (NF1)
Open Access
- 24 June 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0304778
Abstract
Neurofibromatosis type 1 (NF1) is a complex genetic disorder that affects a range of tissues including muscle and bone. Recent preclinical and clinical studies have shown that Nf1 deficiency in muscle causes metabolic changes resulting in intramyocellular lipid accumulation and muscle weakness. These can be subsequently rescued by dietary interventions aimed at modulating lipid availability and metabolism. It was speculated that the modified diet may rescue defects in cortical bone as NF1 deficiency has been reported to affect genes involved with lipid metabolism. Bone specimens were analyzed from wild type control mice as well as Nf1Prx1-/- (limb-targeted Nf1 knockout mice) fed standard chow versus a range of modified chows hypothesized to influence lipid metabolism. Mice were fed from 4 weeks to 12 weeks of age. MicroCT analysis was performed on the cortical bone to examine standard parameters (bone volume, tissue mineral density, cortical thickness) and specific porosity measures (closed pores corresponding to osteocyte lacunae, and larger open pores). Nf1Prx1-/- bones were found to have inferior bone properties to wild type bones, with a 4-fold increase in the porosity attributed to open pores. These measures were rescued by dietary interventions including a L-carnitine + medium-chain fatty acid supplemented chow previously shown to improve muscle histology function. Histological staining visualized these changes in bone porosity. These data support the concept that lipid metabolism may have a mechanistic impact on bone porosity and quality in NF1.Keywords
Funding Information
- Children’s Tumor Foundation Drug Discovery Initiative
- Luminesce Alliance
- Research Training Program (RTP) Scholarships from the Australian Government
- Research Training Program (RTP) Scholarships from the Australian Government
This publication has 28 references indexed in Scilit:
- L‐carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trialAmerican Journal of Medical Genetics Part A, 2021
- Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable TechniquesJournal of Bone and Mineral Research, 2020
- Lipid storage myopathies: Current treatments and future directionsProgress in Lipid Research, 2018
- Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone VolumeCalcified Tissue International, 2018
- Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With Osteomalacia-like Bone PhenotypeJournal of Bone and Mineral Research, 2017
- Neurofibromin inactivation impairs osteocyte development in Nf1Prx1 and Nf1Col1 mouse modelsBone, 2014
- Combined MEK Inhibition and BMP2 Treatment Promotes Osteoblast Differentiation and Bone Healing in Nf1Osx−/− MiceJournal of Bone and Mineral Research, 2014
- Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioningBone, 2005
- Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancerGenesis, 2002
- Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA proteinNature, 1997